efgartigimod
argenx
['vyvgart']
news from #ash22 | phase iii advance study of vyvgart: "the trial results show that the therapy was both efficacious and well tolerated" 
APLUSA is a leading global #healthcare #market #research #consultancy with 30+ years experience.

Follow us for some exclusive French content ??@AplusA_France